Skip to main content
SpringerLink
Log in

Plasminogen activator inhibitor 1: Molecular aspects and clinical importance

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Plasminogen activator inhibitor-1 (PAI-1) is the major physiologic inhibitor of plasminogen activation in plasma and in the blood vessel wall. PAI-1 exhibits distinctive structural and functional properties that have been extensively studied over the past decade. Aside from the physiological role of PAI-1, there is accumulating evidence that increased production of PAI-1 may contribute to the development of ischemic cardiovascular disease. Efforts are now underway to develop and test specific inhibitors of PAI-1.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Van Mourik JA, Lawrence PA, Loskutoff DJ. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells.J Biol Chem 1984;259:14914–14921.

    PubMed  Google Scholar 

  2. Ginsburg D, Zeheb R, Yang A, et al. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells.J Clin Invest 1986;78:1673–1680.

    PubMed  Google Scholar 

  3. Ny T, Sawdey M, Lawrence D, et al. Cloning and sequence of a cDNA coding for the human B-migrating endothelialcell-type plasminogen activator inhibitor.Proc Natl Acad Sci USA 1986;83:6776–6780.

    PubMed  Google Scholar 

  4. Pannekoek H, Veerman H, Lambers H, et al. Endothelial plasminogen activator inhibitor (PAI): A new member of the Serpin gene family.EMBO J 1986;5:2539–2544.

    PubMed  Google Scholar 

  5. Aertgeerts K, DeBondt HL, DeRanter C, et al. A model of the reactive form of plasminogen activator inhibitor-1.J Struct Biol 1994;113:239–245.

    PubMed  Google Scholar 

  6. Kruithof EKO, Tran-Than C, Ransijn A, et al. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma.Blood 1984;64:907–913.

    PubMed  Google Scholar 

  7. Declerck PJ, DeMol M, Alessi MC, et al. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma.J Biol Chem 1988;263:15454–15461.

    PubMed  Google Scholar 

  8. Hekman CM, Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants.J Biol Chem 1985;260:11581–11587.

    PubMed  Google Scholar 

  9. Vaughan DE, Declerck PJ, Reilly TM, et al. Dynamic structural and functional relationships in recombinant plasminogen activator inhibitor-1 (rPAI-1).Biochim Biophys Acta 1993;1202:221–229.

    PubMed  Google Scholar 

  10. Mottonen J, Strand A, Symersky J, et al. Structural basis of latency in plasminogen activator inhibitor-1.Nature 1992;355:270–273.

    PubMed  Google Scholar 

  11. Declerk PJ, Alessi MC, Vevstreken M, et al. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-bound enzyme linked immunosorbent assay.Blood 1988;71:220–225.

    PubMed  Google Scholar 

  12. Carrell RW, Evans DLI, Stein PE. Mobile reactive centre of serpins and the control of thrombosis.Nature 1991;353:576–578.

    PubMed  Google Scholar 

  13. Simon DI, Hui X, Vaughan DE. Cathepsin D mediates the degradation of tissue-type plasminogen activator/plasminogen activator inhibitor complexes in human monocytes.Biochim Biophys Acta 1995, in press.

  14. Vaughan DE, Declerck PJ, Van Houtte E, et al. Studies of recombinant plasminogen activator inhibitor-1 in rabbits: Evidence for reactivation of latent PAI-1 in vivo.Circ Res 1990;67:1281–1286.

    PubMed  Google Scholar 

  15. Lambers JWJ, Cammenga M, Koenig BW, et al. Activation of human endothelial cell-type plasminogen activator inhibitor (PAI-1) by negatively charged phospholipids.J Biol Chem 1988;262:17492–17496.

    Google Scholar 

  16. Declerck PJ, De Mol M, Vaughan DE, et al. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, which is a non-inhibitory substrate for tissue plasminogen activator.J Biol Chem 1992;267:11693–11696.

    PubMed  Google Scholar 

  17. Sancho E, Declerck PJ, Price NC, et al. Conformational studies on plasminogen activator inhibitor (PAI-1) in active, latent, substrate, and cleaved forms.Biochemistry 1995;34:1064–1069.

    PubMed  Google Scholar 

  18. Lawrence DA, Loskutoff DJ. Inactivation of plasminogen activator inhibitor by oxidants.Biochemistry 1986;25:6351–6355.

    PubMed  Google Scholar 

  19. Strandberg L, Lawrence DA, Johansson LBA, et al. The oxidative inactivation of plasminogen activator inhibitor type 1 results from a conformational change in the molecule and does not require the involvement of the Pl' methionine.J Biol Chem 1991;266:13852–13858.

    PubMed  Google Scholar 

  20. Wiman B, Chmielewska J, Ranby M. Inactivation of tissue plasminogen activator in plasma.J Biol Chem 1984;259:3644–3647.

    PubMed  Google Scholar 

  21. Thorsen S, Philips M, Selmer J, et al. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2.EVR Biochem 1988;175:33–39.

    Google Scholar 

  22. Andreasen PA, Nielsen LS, Kristensen P, et al. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme.J Biol Chem 1986;261:7644–7651.

    PubMed  Google Scholar 

  23. Madison EL, Goldsmith EJ, Gerard RD, et al. Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor-1.Proc Natl Acad Sci USA 1990;87:3530–3533.

    PubMed  Google Scholar 

  24. Sprengers ED, Kluft C. Plasminogen activator inhibitors.Blood 1987;69:381–387.

    PubMed  Google Scholar 

  25. Sprengers ED, Princen HMG, Kooistra T, et al. Inhibition of plasminogen activators by conditioned medium of human hepatocytes and hepatoma cell line Hep G2.J Lab Clin Med 1985;105:751.

    PubMed  Google Scholar 

  26. Knudsen BS, Harpel PC, Nachman RL. Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells.J Clin Invest 1987;80:1082–1089.

    PubMed  Google Scholar 

  27. Kruithof EKO, Nicolosa G, Bachmann F. Plasminogen activator inhibitor 1: Development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation.Blood 1987;70:1645–1653.

    PubMed  Google Scholar 

  28. Andreasen PA, Sottrup-Jensen L, Kjoller L, et al. Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes.FEBS Lett 1994;338:239–245.

    PubMed  Google Scholar 

  29. Ehrlick HJ, Gebbink RK, Keijer J, et al. Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties.J Biol Chem 1990;265:13029–13035.

    PubMed  Google Scholar 

  30. Gebbink RK, Reynolds CH, Tollefsen DM, et al. Specific glycosaminoglycans support the inhibition of thrombin by plasminogen activator inhibitor 1.Biochemistry 1993;32:1675–1680.

    PubMed  Google Scholar 

  31. Mimuro J, Schleef RR, Loskutoff DJ. Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor.Blood 1987;70:721–728.

    PubMed  Google Scholar 

  32. Sawdey M, Poder TJ, Loskutoff DJ. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells.J Biol Chem 1989;264:10396–10401.

    PubMed  Google Scholar 

  33. Quax PHA, Hoogen MVD, Verheijen JH, et al.Endotoxin induction of plasminogen activator and plasminogen activator inhibitor type 1 mRNA in rat tissues in vivo.J Biol Chem 1990;265:15560–15563.

    PubMed  Google Scholar 

  34. Lucore CL, Fujii S, Wun TC, et al. Regulation of the expression of type 1 plasminogen activator inhibitor in Hep G2 cells by epidermal growth factor.J Biol Chem 1988;263:15845–15848.

    PubMed  Google Scholar 

  35. Alessi MC, Juhan-Vague I, Kooistra T, et al. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2.Thromb Haemost 1988;60:491–494.

    PubMed  Google Scholar 

  36. Dichek D, Quertermous T. Thrombin regulation of mRNA levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells.Blood 1989;74:222–228.

    PubMed  Google Scholar 

  37. Ridker PM, Gaboury CL, Conlin PR, et al. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II.Circulation 1993;87:1969–1973.

    PubMed  Google Scholar 

  38. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells.J Clin Invest 1995;95:995–1001.

    PubMed  Google Scholar 

  39. Loskutoff DJ, Linders M, Keijer J, et al. Structure of the human plasminogen activator inhibitor 1 gene: Nonrandom distribution of introns.Biochemistry 1987;26:3763–3768.

    PubMed  Google Scholar 

  40. Bosma PJ, VanDenBerg EA, Kooistra T, et al. Human plasminogen activator inhibitor-1 gene: Promoter and structural gene nucleotide sequences.J Biol Chem 1988;263:9129–9141.

    PubMed  Google Scholar 

  41. VanZonneveld AJ, Curriden SA, Loskutoff DJ. Type 1 plasminogen activator inhibitor gene: Functional analysis and glucocorticoid regulation of its promoter.Proc Natl Acad Sci USA 1988;85:5525–5529.

    PubMed  Google Scholar 

  42. Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1).Circulation 1989;79:101–106.

    PubMed  Google Scholar 

  43. Grimado V, Hanert J, Bachman F, et al. Diurnal variation of the fibrinolytic system.Thromb Haemost 1988;59:495–499.

    PubMed  Google Scholar 

  44. Muller JE, Stone PH, Turi ZG, et al. Circadian variation in the frequency of onset of acute myocardial infarction.N Engl J Med 1985;313:1315–1322.

    PubMed  Google Scholar 

  45. Kurnik PB. Circadian variation in the efficacy of tissue-type plasminogen activator.Circulation 1995;91:1341–1346.

    PubMed  Google Scholar 

  46. Schleef RR, Higgins DL, Pillemer E, et al. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor.J Clin Invest 1989;83:1747–1752.

    PubMed  Google Scholar 

  47. Dieval J, Nguyen G, Gross S, et al. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1.Blood 1991;77:528–532.

    PubMed  Google Scholar 

  48. Fay WP, Shapiro AD, Shih JL, et al. Brief report: Complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation.N Engl J Med 1992;327:1729–1733.

    PubMed  Google Scholar 

  49. Carmeliet P, Stassen JM, Schoonjans L, et al. Plasminogen activator inhibitor-1 gene-deficient mice II. Effects on hemostasis, thrombosis, and thrombolysis.J Clin Invest 1993;92:2756–2760.

    PubMed  Google Scholar 

  50. Schneiderman J, Sawdey MS, Keeton MR, et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries.Proc Natl Acad Sci USA 1992;89:6998–7002.

    PubMed  Google Scholar 

  51. Hamsten A, Eriksson P. Fibrinolysis and atherosclerosis: An update.Fibrinolysis 1994;8:253–262.

    Google Scholar 

  52. Juhan-Vague I, Valadier J, Alessi MC, et al. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis.Thromb Haemost 1987;57:67–72.

    PubMed  Google Scholar 

  53. Hamsten A, Wiman B, Faire UD, et al. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.N Engl J Med 1985;313:1557–1563.

    PubMed  Google Scholar 

  54. Hamsten A, Walldius G, Szamosi A, et al. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction.Lancet 1987:3–9

  55. Meade TW, Ruddock V, Stirling Y, et al. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study.Lancet 1993;342:1076–1079.

    PubMed  Google Scholar 

  56. Juhan-Vague I, Thompson SG, Jespersen J on behalf of the ECAT Angina Pectoris Study Group. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris.Arterioscler Thromb 1993;13:1865–1873.

    PubMed  Google Scholar 

  57. Ridker PM, Vaughan DE, Stampfer MJ, et al. Endogenous tissue-type plasminogen activator and the risk of future myocardial infarction.Lancet 1993;341:1165–1168.

    PubMed  Google Scholar 

  58. Ridker PM, Hennekens CH, Stampfer MJ, et al. A prospective study of tissue-type plasminogen activator and the risk of stroke.Lancet 1994;434:940–943.

    Google Scholar 

  59. Eriksson P, Kallin B, Hooft FM, et al. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction.Proc Natl Acad Sci USA 1995;92:1851–1855.

    PubMed  Google Scholar 

  60. Grimado V, Bachman F, Kruithof EKO. Antigen levels of plasminogen activator inhibitor type-1 in citrated plasma: Determination of the contribution of platelets.Haemostasis 1990;20:329–333.

    PubMed  Google Scholar 

  61. Ranby M, Sundell IB, Nilsson TK. Blood collection in strong acid citrate anticoagulant used in a study of dietary influence on basal t-PA activity.Thromb Haemost 1989;62:917–922.

    PubMed  Google Scholar 

  62. Keyt BA, Paoni NF, Refino CJ, et al. A faster-acting and more potent form of tissue plasminogen activator.Proc Natl Acad Sci USA 1994;91:3670–3674.

    PubMed  Google Scholar 

  63. Levi M, Biemond BJ, Zonneveld AV, et al. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis.Circulation 1992;85:305–312.

    PubMed  Google Scholar 

  64. Eitzman DT, Fay WT, Lawrence DA, et al. Peptidemediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro.J Clin Invest 1995;95:2416–2420.

    PubMed  Google Scholar 

  65. Sawa H, Sobel BE, Fujii S. Inhibition of type-1 plasminogen activator inhibitor production by antisense oligonucleotides in human vascular endothelial and smooth muscle cells.J Biol Chem 1994;269:14149–14152.

    PubMed  Google Scholar 

  66. Kojima S, Muramatsu H, Amanuma H, et al. Midkine enhances fibrinolytic activity of bovine endothelial cells.J Biol Chem 1995;270:9560–9596.

    Google Scholar 

  67. Pfeffer MA, Braunwald LA, Moye L, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction.N Engl J Med 1992;327:669–677.

    PubMed  Google Scholar 

  68. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions.Lancet 1992;340:1173–1178.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiology Division, Vanderbilt University Medical Center,Veterans Administration Medical Center, Nashville, TN

    Douglas E. Vaughan

Authors
  1. Douglas E. Vaughan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vaughan, D.E. Plasminogen activator inhibitor 1: Molecular aspects and clinical importance. J Thromb Thrombol 2, 187–193 (1995). https://doi.org/10.1007/BF01062709

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01062709

Key words

Search

Navigation